TNF receptor-associated factor 6 (TRAF6)

TNF receptor-associated factor 6 (TRAF6) is a pivotal adapter protein and E3 ubiquitin ligase that serves as a central hub in the signaling pathways of the Toll-like receptor (TLR), interleukin-1 receptor (IL-1R), and tumor necrosis factor receptor (TNFR) superfamilies [1.1.2, 1.3.4]. Unlike other TRAF family members, TRAF6 is unique in its ability to mediate signals from both the TNFR and IL-1R/TLR families, facilitating the activation of downstream transcription factors such as NF-kappaB and AP-1 [1.1.2, 1.3.1]. It functions by catalyzing the formation of Lys63-linked polyubiquitin chains, which act as scaffolds for the recruitment and activation of kinases like TAK1 and the IKK complex [1.3.4]. Dysregulation of TRAF6 is strongly associated with chronic inflammatory conditions, autoimmune diseases like rheumatoid arthritis and psoriasis, and various cancers where it promotes tumor cell survival, invasion, and metastasis [1.1.4, 1.4.3]. In some contexts, such as myeloid malignancies, TRAF6 may also act as a tumor suppressor, complicating its role as a therapeutic target [1.4.2]. Current drug development efforts are focused on small-molecule inhibitors, such as C25-140, which disrupt the interaction between TRAF6 and its E2 conjugating enzyme Ubc13 to suppress pathological signaling [1.2.2, 1.2.4].

Other names

RNF85E3 ubiquitin-protein ligase TRAF6Interleukin-1 receptor-associated kinase-binding proteinMGC:3310

Inhibition of E3 ubiquitin ligase activity and disruption of protein-protein interactions (e.g., TRAF6-Ubc13, CD40-TRAF6, or RANK-TRAF6)